Payne S D, Resnik R, Moore T R, Hedriana H L, Kelly T F
Department of Reproductive Medicine, University of California, San Diego Medical Center, La Jolla 92093-0621, USA.
Am J Obstet Gynecol. 1997 Jul;177(1):149-55. doi: 10.1016/s0002-9378(97)70454-x.
The antenatal and intrapartum management of women with autoimmune thrombocytopenia is controversial. The current approach emphasizes an effort to identify maternal characteristics predictive of severe neonatal thrombocytopenia or to measure fetal platelet counts and perform cesarean section in patients considered to be at risk for neonatal intracranial hemorrhage. In the current study we review our experience with maternal autoimmune thrombocytopenia and neonatal outcome.
Fifty-five pregnancies with autoimmune thrombocytopenia over a 10-year period in three major medical centers in San Diego, California, were evaluated. Maternal characteristics and neonatal outcomes were assessed and compared with those in other recent reports. Data were submitted to Fisher's exact (two-tailed), chi2, and Student t tests, with linear regression performed to analyze the association between variables.
Maternal characteristics including platelet count, presence of antiplatelet antibody, antecedent history of autoimmune thrombocytopenia, and corticosteroid therapy were not predictive of severe neonatal thrombocytopenia. Maternal history of splenectomy was significantly correlated with fetal platelet counts <50 x 10(9)/L (odds ratio 5.63; 95% confidence interval 2.2 to 14.3). There were four neonates with severe neonatal thrombocytopenia (8%), and one who was delivered by cesarean section had intracranial hemorrhage.
These findings, combined with others in the literature, confirm that severe neonatal thrombocytopenia is an infrequent complication of maternal autoimmune thrombocytopenia and is not reliably predicted by maternal characteristics. Intracranial hemorrhage is also a rare event and is not related to mode of delivery. Cesarean section should be reserved for obstetric indications only.
自身免疫性血小板减少症女性的产前及产时管理存在争议。目前的方法着重于努力识别可预测严重新生儿血小板减少症的母体特征,或测量胎儿血小板计数,并对被认为有新生儿颅内出血风险的患者实施剖宫产。在本研究中,我们回顾了我们在母体自身免疫性血小板减少症及新生儿结局方面的经验。
对加利福尼亚州圣地亚哥市三个主要医疗中心10年间的55例自身免疫性血小板减少症妊娠进行了评估。评估母体特征及新生儿结局,并与其他近期报告中的情况进行比较。数据采用Fisher精确检验(双侧)、卡方检验及Student t检验,并进行线性回归以分析变量之间的关联。
包括血小板计数、抗血小板抗体的存在、自身免疫性血小板减少症既往史及皮质类固醇治疗在内的母体特征并不能预测严重新生儿血小板减少症。脾切除术的母体病史与胎儿血小板计数<50×10⁹/L显著相关(优势比5.63;95%置信区间2.2至14.3)。有4例新生儿发生严重新生儿血小板减少症(8%),1例剖宫产分娩的新生儿发生了颅内出血。
这些发现,与文献中的其他发现相结合,证实严重新生儿血小板减少症是母体自身免疫性血小板减少症的一种罕见并发症,且不能通过母体特征可靠地预测。颅内出血也是罕见事件,与分娩方式无关。剖宫产仅应保留用于产科指征。